Clinical evaluation of amitraz as a treatment for canine demodicosis.
A liquid concentrate formulation of amitraz was clinically evaluated in 1721 canines showing demodicosis, by 25 veterinary investigators. The therapy was applied topically at 14-day intervals, and at a concentration of 250 ppm active drug in water. The miticide was efficacious and safe; approximately 99% of the canines showing localized or generalized demodicosis became clinically normal, and the side-effects recorded were minimal and transient. Approximately 3/4 of the patients were pure-bred animals and the majority were less than 1 year old. The clinical data support the conclusion that amitraz (liquid concentrate) is efficacious and safe for treating canine demodicosis.
D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D007306:Insecticides / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008924:Mite Infestations / Q000188:drug therapy / Q000662:veterinary*; D012449:Safety; D014052:Toluidines / Q000008:administration & dosage / Q000627:therapeutic use*
D007306:Insecticides; D014052:Toluidines; C014983:amitraz